SCHEMBL3454628

SCHEMBL3454628

Nc1ccc2c(c1)N(C(=O)c1ccccc1)CC2

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.68
ALDH1A1 P00352 1/20 0.68
AVPR2 P30518 2/20 0.57
AVPR1A P37288 2/20 0.57
RAB9A P51151 6/20 0.54
NPC1 O15118 4/20 0.54
KMT2A Q03164 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
GAA P10253 1/20 0.53
HTT P42858 1/20 0.53
MEN1 O00255 2/20 0.51
STAT3 P40763 1/20 0.50
BRD4 O60885 1/20 0.50
ATAD2 Q6PL18 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
SLC22A12 Q96S37 1/20 0.47
HSD17B3 P37058 1/20 0.47
OXTR P30559 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3454890 0.92 AVPR2 (0.65) HPGDALDH1A1AVPR2AVPR1ARAB9A
SCHEMBL15712623 0.88 HPGD (0.68) HPGDALDH1A1AVPR2AVPR1ARAB9A
SCHEMBL11031260 0.84 HPGD (0.69) HPGDALDH1A1AVPR2AVPR1ARAB9A
SCHEMBL3461334 0.83 BRD4 (0.56) HPGDALDH1A1AVPR2AVPR1ARAB9A
SCHEMBL8620609 0.82 HPGD (0.68) HPGDALDH1A1AVPR2AVPR1ARAB9A
SCHEMBL31556814 0.81 HPGD (1.00) HPGDALDH1A1AVPR2AVPR1ARAB9A
SCHEMBL5783412 0.81 HPGD (1.00) HPGDALDH1A1AVPR2AVPR1ARAB9A
SCHEMBL28771923 0.80 RAB9A (0.65) HPGDALDH1A1AVPR2AVPR1ARAB9A
SCHEMBL3462953 0.79 NPC1 (0.70) RAB9ANPC1SMN1; SMN2
SCHEMBL21348490 0.79 HPGD (0.62) HPGDALDH1A1RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
EP-2254889-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF Merck Patent GmbH (DE) 2010-12-01 EP disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed
WO-1998050346-A2 ACETAMIDE AND UREA DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CNS DISORDERS SMITHKLINE BEECHAM PLC (GB) 1998-11-12 WO disclosed
EP-0127634-A1 PYRROLOCOUMARIN DERIVATIVES, THEIR MANUFACTURE AND UTILISATION KATHOLIEKE UNIVERSITEIT TE LEUVEN (BE) 1984-12-12 EP disclosed
WO-1984002133-A1 PYRROLOCOUMARIN DERIVATIVES, THEIR MANUFACTURE AND UTILISATION UNIV LEUVEN KATH (BE) 1984-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 HPGD 2363/4885ALDH1A1 4501/4885AVPR2 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.